{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:45:59Z","timestamp":1762980359719,"version":"build-2065373602"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.12.006","type":"journal-article","created":{"date-parts":[[2016,12,19]],"date-time":"2016-12-19T15:47:24Z","timestamp":1482162444000},"page":"209-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Classifying the additional morbidities of Gaucher disease"],"prefix":"10.1016","volume":"68","author":[{"given":"Mirjam","family":"Langeveld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Elstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Szer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla E.M.","family":"Hollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"Blood Cells Mol. Dis.","year":"2016","author":"Biegstraaten","key":"10.1016\/j.bcmd.2016.12.006_bb0005"},{"issue":"6","key":"10.1016\/j.bcmd.2016.12.006_bb0010","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/bjh.12335","article-title":"Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature","volume":"161","author":"Arends","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.bcmd.2016.12.006_bb0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","article-title":"Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism","volume":"18","author":"Mistry","year":"2013","journal-title":"Crit. Rev. Oncog."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2016.12.006_bb0020","first-page":"S25","article-title":"Gaucher disease and comorbidities: B-cell malignancy and parkinsonism","volume":"90","author":"Cox","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"374(6)","key":"10.1016\/j.bcmd.2016.12.006_bb0025","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa1508808","article-title":"Clonal immunoglobulin against lysolipids in the origin of myeloma","volume":"115","author":"Nair","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcmd.2016.12.006_bb0030","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S1096-7192(03)00071-4","article-title":"Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism","volume":"79","author":"Tayebi","year":"2003","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2016.12.006_bb0035","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/jnc.13385","article-title":"The relationship between glucocerebrosidase mutations and Parkinson disease","volume":"139","author":"Migdalska-Richards","year":"2016","journal-title":"J. Neurochem."},{"issue":"9","key":"10.1016\/j.bcmd.2016.12.006_bb0040","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.bcmd.2016.12.006_bb0045","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/mds.26802","article-title":"Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease","volume":"31","author":"Wong","year":"2016","journal-title":"Mov. Disord."},{"journal-title":"Blood Cells Mol. Dis.","year":"2016","author":"Ishay","key":"10.1016\/j.bcmd.2016.12.006_bb0050"},{"key":"10.1016\/j.bcmd.2016.12.006_bb0055","first-page":"30225","article-title":"Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease","volume":"16","author":"Nascimbeni","year":"2016","journal-title":"Blood Cells Mol. Dis."},{"issue":"3","key":"10.1016\/j.bcmd.2016.12.006_bb0060","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy","volume":"40","author":"Langeveld","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.12.006_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010324.pub2","article-title":"Enzyme replacement and substrate reduction therapy for Gaucher disease","author":"Shemesh","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bcmd.2016.12.006_bb0070","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.2147\/DDDT.S77760","article-title":"Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease","volume":"9","author":"Bennett","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bcmd.2016.12.006_bb0075","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","author":"Maison-Blanche","year":"2016","journal-title":"Eur J. Intern. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616303217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616303217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:32Z","timestamp":1761050072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616303217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":15,"alternative-id":["S1079979616303217"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.12.006","relation":{},"ISSN":["1079-9796"],"issn-type":[{"type":"print","value":"1079-9796"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classifying the additional morbidities of Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}